Conditions: Advanced Metastatic Soft Tissue Sarcoma
Keywords: ENMD-2076 advanced metastatic soft tissue sarcoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
This is a phase 2 study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. This study will help to understand how well ENMD-2076 works and how safe and tolerable the drug is in this patient population.

Detailed description:
ENMD-2076 is an oral drug that works by blocking certain enzymes called Aurora A from working. These enzymes are needed for cells to divide including cancer cells. ENMD-2076 also works by stopping the growth of new blood vessels which would provide the tumor with nutrients for it to grow. It is believed that by blocking Aurora A enzymes from working and stopping new blood vessels from growing, the tumors may stop growing or shrink.

Arms:
arm 1: ENMD-2076 capsules, 275 mg once daily, by mouth.

Interventions: intervention 1: ENMD-2076
Intervention descriptions: intervention 1: None

Protocol document: